WhittingtonR., FauldsD.Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs1993; 46: 446–514.
2.
HuberC., BatchelorJ.R., FuchsD.. Immune response-associated production of neopterin: release from macrophages primarily under control of interferon-gamma.J Exp Med1984; 160: 310–6.
3.
RubinL.A., KurmanC.C., FritzM.E.. Soluble interleukin-2 receptors are released by activated lymphocytes in vitro.J Immunol1985; 135: 3172–7.
4.
LissoniP., PittalisS., BrivioF.. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.Cancer1993; 71: 2076–81.
5.
LissoniP., RovelliF., TisiE.. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.J Biol Regul Homeost Agents1995; 9: 146–9.
6.
BanksR.E., PatelP.M., SelbyP.J.Interleukin-12: a new clinical player in cytokine therapy.Br J Cancer1995; 71: 655–9.
7.
LissoniP., FumagalliL., BarniS.. Prognostic significance of changes in IL-12 secretion during cancer immunotherapy with IL-2: preliminary considerations.Int J Immunother, in press.
